Top broker says CSL Limited should still be on your buy list

Shares in biopharmaceutical ASX-star stock CSL Limited (ASX: CSL) can’t be called cheap, but UBS still has a buy rating on the stock, which was sitting at $169.71 at the time of writing.

UBS labels the stock a buy with a price target of $175 with US industry data convincing the broker there’s still plenty of growth potential in the pipeline for the company.

CSL is currently trading about 20% above its 200-day moving average in an upward trend, with peer Cochlear Limited (ASX: COH) also trending upwards in a similar fashion with Cochlear’s price up 1% to $197.01 today and no signs of a slowdown.

Both companies have likely fared well from a plunging Australian dollar thanks to their US earnings, while globally-focused healthcare players like Sonic Healthcare Limited (ASX: SHL) have also begun to correct from a recent downturn with prices heading up 0.6% to $23.90 at the time of writing. This as the company works to strengthen its presence overseas.

CSL is a revolutionary stock, no doubt about it, check out these 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.